NCT00509262View on ClinicalTrials.gov

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

PHASE3CompletedINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

October 9, 2007

Primary Completion Date

March 16, 2011

Study Completion Date

March 16, 2011

Conditions
Diabetes Mellitus, Type 2Renal Insufficiency, Chronic
Interventions
DRUG

Sitagliptin

Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily

DRUG

Glipizide

Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)

DRUG

Placebo for Sitagliptin

Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily

DRUG

Placebo for Glipizide

Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00509262 - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) | Biotech Hunter | Biotech Hunter